SCHEMBL720105

SCHEMBL720105

COc1ccc2cc(C(Nc3ccc(C(=O)NCCC(=O)O)cc3)C3CCCCC3)oc2c1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.47
RAB9A P51151 2/20 0.47
KDM4E B2RXH2 1/20 0.47
HPGD P15428 1/20 0.47
HSD17B10 Q99714 1/20 0.47
GCG P01275 12/20 0.45
NPC1 O15118 1/20 0.43
MDM2 Q00987 1/20 0.43
SMN1; SMN2 Q16637 1/20 0.43
GCGR P47871 3/20 0.43
GLP1R P43220 1/20 0.43
GIPR P48546 1/20 0.43
ADCY6 O43306 1/20 0.41
ADCY3 O60266 1/20 0.41
ADCY9 O60503 1/20 0.41
ADCY5 O95622 1/20 0.41
ADCY8 P40145 1/20 0.41
ADCY7 P51828 1/20 0.41
ADCY2 Q08462 1/20 0.41
ADCY1 Q08828 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL717279 0.94 GCG (0.44) ALDH1A1RAB9AKDM4EHPGDHSD17B10
SCHEMBL720269 0.88 ALDH1A1 (0.50) ALDH1A1RAB9AKDM4EHPGDHSD17B10
SCHEMBL720111 0.87 ALDH1A1 (0.43) ALDH1A1RAB9AKDM4EHPGDHSD17B10
SCHEMBL718231 0.86 ALDH1A1 (0.50) ALDH1A1RAB9AKDM4EHPGDHSD17B10
SCHEMBL721161 0.84 NPC1 (0.50) ALDH1A1RAB9AKDM4EGCGNPC1
SCHEMBL718009 0.84 ADORA2A (0.47) ALDH1A1RAB9AKDM4EHPGDHSD17B10
SCHEMBL719515 0.83 NPC1 (0.43) ALDH1A1RAB9AKDM4EGCGNPC1
SCHEMBL720121 0.81 GCG (0.42) ALDH1A1RAB9AGCGNPC1MDM2
SCHEMBL718424 0.80 HSD17B10 (0.41) ALDH1A1RAB9AKDM4EHPGDHSD17B10
SCHEMBL3403102 0.80 GCG (0.45) ALDH1A1RAB9AGCGNPC1MDM2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8436043-B2 Heterocyclic compound TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2013-05-07 US disclosed
US-8436043-B2 Heterocyclic compound TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2013-05-07 US disclosed
US-8436043-B2 Heterocyclic compound TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2013-05-07 US disclosed
US-20120270865-A2 HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2012-10-25 US disclosed
US-20120270865-A2 HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2012-10-25 US disclosed
US-20120053173-A1 HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2012-03-01 US disclosed
US-20120053173-A1 HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2012-03-01 US disclosed
EP-2251326-A1 HETEROCYCLIC COMPOUND Takeda Pharmaceutical Company Limited (JP) 2010-11-17 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120053173-A1 HETEROCYCLIC COMPOUND SLC5A2, SLC5A1, IAPP ALDH1A1 504/4885RAB9A 2454/4885KDM4E 1907/4885
US-20120270865-A2 HETEROCYCLIC COMPOUND SLC5A2, SLC5A1, IAPP ALDH1A1 504/4885RAB9A 2454/4885KDM4E 1907/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.